News

Ad hoc: Medigene announces Start of Phase II trial with DC vaccines and upcoming milestone payment

Martinsried/Munich, 01 April 2016. Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company, announced the treatment start of the first phase II-patient in its dendritic cell (DC) vaccine clinical phase I/II trial in acute myeloid leukaemia (AML). This triggers a milestone payment in the amount of approx. 3.2 m EUR to be made by Medigene AG to former contributing shareholders of Medigene Immunotherapies GmbH (formerly: Trianta Immunotherapies GmbH) within the next five months. Medigene intends to settle this payment through the issuance of new shares from authorised capital. The milestone payment was an agreed part of the purchase price in the acquisition of Trianta in January 2014. 

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Lochhamer Str. 11 82152
Planegg/Martinsried, Germany
Tel.: +49 - 89 - 20 00 33 - 33 01,
Email: investor@medigene.com